GB2597315A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with congenital disorder of glycosylation 1P. The seizures associated with congenital disorder of glycosylation 1P can be tonic and myoclonic seizures. The CBD preparation can comprise greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation can comprise less than or equal to 2% (w/w) other cannabinoids comprising THC, cannabidiol C-1 (CBD-C1), cannabidivarin (CBDV), or cannabidiol C-4 (CBD-C4). The THC can be present as a mixture of trans-THC and cis-THC. The CBD preparation can be used in combination with other anti-epileptic drugs (AED). The AED can be levetiracetam and/or rufinamide. The CBD can be isolated from cannabis plant material. The CBD can be present as a synthetic preparation. The CBD preparation can be used at a dose greater than 5 mg/kg/day (e.g. 20, 25, or 50 mg/kg/day). A further aspect of the invention is a method of treating seizures associated with congenital disorder of glycosylation 1P comprising administering a CBD preparation to a subject.